SCHEMBL5367333

SCHEMBL5367333

O=C1Nc2ccc(CCCl)cc2C1=Cc1cc([N+](=O)[O-])ccc1O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOX4 Q9NPH5 1/20 0.58
GSK3B P49841 7/20 0.51
RET P07949 2/20 0.49
PDGFRB P09619 1/20 0.48
JAK3 P52333 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
ALPG P10696 1/20 0.47
HPGD P15428 1/20 0.47
DHFR P00374 1/20 0.47
CCNE1 P24864 1/20 0.45
CDK2 P24941 1/20 0.45
CAPN9 O14815 1/20 0.43
CASP3 P42574 1/20 0.43
APP P05067 1/20 0.42
SNCA P37840 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364633 0.85 NOX4 (0.45) NOX4GSK3BRETPDGFRBJAK3
SCHEMBL5367186 0.84 LRRK2 (0.53) PDGFRB
SCHEMBL7136333 0.84 MAPT (0.61) NOX4GSK3BRETPDGFRBJAK3
SCHEMBL5377096 0.83 PLK4 (0.55) RETPDGFRBMEN1KMT2A
SCHEMBL5366154 0.82 NOX4 (0.44) NOX4GSK3BRETMEN1KMT2A
SCHEMBL7135240 0.82 KDR (0.44) NOX4GSK3BRETPDGFRBJAK3
SCHEMBL5366866 0.82 NOX4 (0.58) NOX4GSK3BKMT2AMAPTALDH1A1
SCHEMBL5368427 0.80 MDM2 (0.53) GSK3BRETPDGFRBJAK3MAPT
SCHEMBL5369296 0.80 NOX4 (0.58) NOX4GSK3BMAPTAPPSNCA
SCHEMBL5374178 0.78 MAP3K7 (0.48) GSK3BPDGFRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK NOX4 3452/4885GSK3B 315/4885RET 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.